Relatively new beta-lactam antibiotics with increased efficacy against gram-negative bacteria have been used in difficult-to-treat infections, such as Pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis. The potential for development of broad-spectrum beta-lactam resistance by induction or derepression of chromosomal beta-lactamase has been recognized and has prompted recommendations for careful use of these agents to prevent the spread of multiply resistant bacteria (11) . In the treatment of pulmonary P. aeruginosa infections with these agents, the detection of resistant isolates by different groups of researchers has been quite variable (2, (4) (5) (6) .
In this study, P. aeruginosa sputum isolates were obtained before, during, and after therapy with ceftazidime and tobramycin (135 mg of ceftazidime per kg [body weight] plus 13.5 mg of tobramycin per kg per day for 14 days). Different morphological types were quantitated and tested for susceptibility to ticarcillin, piperacillin, cefsulodin, ceftazidirne, and aztreonam by disk diffusion (10) . We observed a pattern of resistance at our institution in which broad-spectrum beta-lactam resistance is evident during but not before or after treatment (Fig. 1 ). These observations have several implications for the detection of resistance. First, the detection of resistance during therapy suggests that the timing of isolation and testing for resistance in relation to therapy may be critical and may partly explain the apparent discrepancies in the literature. Serial determinations of both sputum bacterial counts and susceptibility during therapy may be essential for evaluation and correlation of clinical and bacteriological improvements. Second, the reduction of resistant isolates after therapy suggests that the gradual accumulation of resistant isolates during beta-lactam therapy in patients with cystic fibrosis is much less likely than originally anticipated.
To determine the mechanism of resistance and factors involved in the reduction of resistance after therapy, representative isolates were obtained from the patient with cystic fibrosis described in the legend to Fig. 1 25 ,ug of nitrocefin per ml in 50 mM sodium phosphate (pH 7.0) detected high levels of beta-lactamase in all the resistant mutants tested. The resistant mutants 4018m and 4029m, derived from the susceptible isolates 4018 and 4029, were selected for further study.
The pattern of antibiotic susceptibility to a selection of beta-lactam antibiotics was determined for strains 4018, 4023, and 4029 and mutants 4018m and 4029m (Table 1) . Susceptibility testing was performed by using the disk diffusion method of Bauer et al. (1) . MICs were determined in Mueller-Hinton broth with an inoculum of 105 CFU/ml. High levels of resistance to most of the beta-lactams tested were observed in clinical resistant isolate 4023 and laboratoryderived resistant mutants 4018m and 4029m. The patterns of resistance of the three isolates were very similar, suggesting that a primary mechanism of resistance was common to all of them.
To determine whether chromosomal beta-lactamase could be the primary resistance mechanism, levels of betalactamase in susceptible and resistant isolates were com- pared (Table 2 ). Beta-lactamase activity was determined by spectrophotometric assay (9) with 100 p.M cephalothin in 50 mM sodium phosphate buffer (pH 7.0). The hydrolysis was monitored at 262 nm. Crude extracts were prepared by French press lysis of cells from mid-log-phase cultures grown in the presence or absence of 0.25 p.g of imipenem per ml, followed by centrifugation at 180,000 x g for 1 h to remove membranes and cell debris. The results (Table 2) indicate that in the absence of inducer, all of the resistant isolates had enzyme levels at least 1,000-fold higher than those of susceptible isolates. Even after induction, enzyme levels were 20-fold higher in the resistant isolates.
The effect of crude extracts on the tested beta-lactams was examined to determine whether the beta-lactamase could be responsible for the observed resistance pattern. The assay system used was the double-disk technique of Masuda et al. (8) , in which reduction of the zone of inhibition of a particular beta-lactam on a susceptible indicator strain (3) by 30 1.l of crude extract applied to a disk is measured. The crude extracts from the resistant isolates reduced the zone of inhibition of all the beta-lactams tested ( Table 1 ). The zone reductions for ceftazidime and cefsulodin were small but reproducible.
In an attempt to determine the factors responsible for the loss of resistant isolates after cessation of therapy, growth studies with the clinical and laboratory isolates were done. Cells from fresh overnight tryptic soy broth plates were suspended in prewarmed M9 medium (7) containing 4% tryptic soy broth to a starting A600 of 0.1 and incubated at 37°C with shaking throughout the experiment. The growth rates of susceptible strains 4018 (doubling time, 70 min) and 4029 (doubling time, 90 min) were nearly twice those of the clinical or laboratory-derived resistant isolates (doubling times, 120 min for strain 4018m and 145 min for 4023 and 4029m). In mixed-culture experiments on nonselective medium, the susceptible isolates repeatedly outgrew the resistant isolates (data not shown); this finding is consistent with Our observations suggest that resistance due primarily to elevated levels of beta-lactamase may emerge during therapy with newer beta-lactams but may be overlooked in treatment failures if only pre-and posttherapy bacterial isolates are evaluated. The decline of resistant isolates after cessation of therapy may be explained by a selective growth advantage of susceptible isolates observed in medium without antibiotics.
